|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAJC19 |
Gene summary for DNAJC19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAJC19 | Gene ID | 131118 |
| Gene name | DnaJ heat shock protein family (Hsp40) member C19 | |
| Gene Alias | PAM18 | |
| Cytomap | 3q26.33 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q96DA6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 131118 | DNAJC19 | LZE2T | Human | Esophagus | ESCC | 2.38e-07 | 1.39e+00 | 0.082 |
| 131118 | DNAJC19 | LZE4T | Human | Esophagus | ESCC | 1.17e-16 | 6.55e-01 | 0.0811 |
| 131118 | DNAJC19 | LZE5T | Human | Esophagus | ESCC | 3.74e-03 | 6.68e-01 | 0.0514 |
| 131118 | DNAJC19 | LZE7T | Human | Esophagus | ESCC | 1.07e-12 | 1.05e+00 | 0.0667 |
| 131118 | DNAJC19 | LZE8T | Human | Esophagus | ESCC | 1.43e-03 | 4.21e-01 | 0.067 |
| 131118 | DNAJC19 | LZE20T | Human | Esophagus | ESCC | 4.37e-07 | 6.08e-01 | 0.0662 |
| 131118 | DNAJC19 | LZE22T | Human | Esophagus | ESCC | 4.54e-08 | 8.53e-01 | 0.068 |
| 131118 | DNAJC19 | LZE24T | Human | Esophagus | ESCC | 8.00e-30 | 9.87e-01 | 0.0596 |
| 131118 | DNAJC19 | LZE21T | Human | Esophagus | ESCC | 2.41e-08 | 1.12e+00 | 0.0655 |
| 131118 | DNAJC19 | LZE6T | Human | Esophagus | ESCC | 4.64e-08 | 8.00e-01 | 0.0845 |
| 131118 | DNAJC19 | P1T-E | Human | Esophagus | ESCC | 1.80e-14 | 1.11e+00 | 0.0875 |
| 131118 | DNAJC19 | P2T-E | Human | Esophagus | ESCC | 5.37e-82 | 1.75e+00 | 0.1177 |
| 131118 | DNAJC19 | P4T-E | Human | Esophagus | ESCC | 1.65e-69 | 2.33e+00 | 0.1323 |
| 131118 | DNAJC19 | P5T-E | Human | Esophagus | ESCC | 1.30e-84 | 1.87e+00 | 0.1327 |
| 131118 | DNAJC19 | P8T-E | Human | Esophagus | ESCC | 9.56e-75 | 1.32e+00 | 0.0889 |
| 131118 | DNAJC19 | P9T-E | Human | Esophagus | ESCC | 8.41e-52 | 1.35e+00 | 0.1131 |
| 131118 | DNAJC19 | P10T-E | Human | Esophagus | ESCC | 8.05e-95 | 1.83e+00 | 0.116 |
| 131118 | DNAJC19 | P11T-E | Human | Esophagus | ESCC | 1.47e-24 | 1.53e+00 | 0.1426 |
| 131118 | DNAJC19 | P12T-E | Human | Esophagus | ESCC | 8.11e-105 | 2.42e+00 | 0.1122 |
| 131118 | DNAJC19 | P15T-E | Human | Esophagus | ESCC | 8.78e-66 | 1.81e+00 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0017038110 | Skin | cSCC | protein import | 100/4864 | 206/18723 | 2.50e-12 | 1.36e-10 | 100 |
| GO:007180610 | Skin | cSCC | protein transmembrane transport | 33/4864 | 59/18723 | 9.93e-07 | 1.78e-05 | 33 |
| GO:00650027 | Skin | cSCC | intracellular protein transmembrane transport | 28/4864 | 51/18723 | 1.05e-05 | 1.37e-04 | 28 |
| GO:006145825 | Skin | cSCC | reproductive system development | 149/4864 | 427/18723 | 2.30e-05 | 2.65e-04 | 149 |
| GO:004860824 | Skin | cSCC | reproductive structure development | 148/4864 | 424/18723 | 2.40e-05 | 2.74e-04 | 148 |
| GO:199054224 | Skin | cSCC | mitochondrial transmembrane transport | 43/4864 | 102/18723 | 2.68e-04 | 2.16e-03 | 43 |
| GO:00301504 | Skin | cSCC | protein import into mitochondrial matrix | 12/4864 | 20/18723 | 1.34e-03 | 8.54e-03 | 12 |
| GO:00447434 | Skin | cSCC | protein transmembrane import into intracellular organelle | 18/4864 | 36/18723 | 1.70e-03 | 1.04e-02 | 18 |
| GO:0072594112 | Thyroid | PTC | establishment of protein localization to organelle | 244/5968 | 422/18723 | 1.18e-28 | 4.97e-26 | 244 |
| GO:0006457112 | Thyroid | PTC | protein folding | 137/5968 | 212/18723 | 8.29e-23 | 2.01e-20 | 137 |
| GO:0006605113 | Thyroid | PTC | protein targeting | 180/5968 | 314/18723 | 6.81e-21 | 1.19e-18 | 180 |
| GO:000683928 | Thyroid | PTC | mitochondrial transport | 150/5968 | 254/18723 | 2.76e-19 | 3.34e-17 | 150 |
| GO:0070585112 | Thyroid | PTC | protein localization to mitochondrion | 83/5968 | 125/18723 | 2.15e-15 | 1.56e-13 | 83 |
| GO:0072655112 | Thyroid | PTC | establishment of protein localization to mitochondrion | 80/5968 | 120/18723 | 4.87e-15 | 3.30e-13 | 80 |
| GO:0006626111 | Thyroid | PTC | protein targeting to mitochondrion | 67/5968 | 100/18723 | 5.55e-13 | 2.74e-11 | 67 |
| GO:0017038111 | Thyroid | PTC | protein import | 109/5968 | 206/18723 | 2.74e-10 | 8.96e-09 | 109 |
| GO:199054225 | Thyroid | PTC | mitochondrial transmembrane transport | 57/5968 | 102/18723 | 4.49e-07 | 7.38e-06 | 57 |
| GO:0061458112 | Thyroid | PTC | reproductive system development | 173/5968 | 427/18723 | 8.70e-05 | 7.23e-04 | 173 |
| GO:0048608111 | Thyroid | PTC | reproductive structure development | 170/5968 | 424/18723 | 1.86e-04 | 1.41e-03 | 170 |
| GO:007180617 | Thyroid | PTC | protein transmembrane transport | 32/5968 | 59/18723 | 3.06e-04 | 2.14e-03 | 32 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAJC19 | SNV | Missense_Mutation | novel | c.70N>A | p.Gln24Lys | p.Q24K | Q96DA6 | protein_coding | tolerated(0.21) | benign(0.06) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| DNAJC19 | SNV | Missense_Mutation | rs199774384 | c.251N>A | p.Arg84Gln | p.R84Q | Q96DA6 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNAJC19 | SNV | Missense_Mutation | novel | c.220N>T | p.Asn74Tyr | p.N74Y | Q96DA6 | protein_coding | deleterious(0.01) | possibly_damaging(0.831) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| DNAJC19 | SNV | Missense_Mutation | c.119N>C | p.Leu40Pro | p.L40P | Q96DA6 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DNAJC19 | SNV | Missense_Mutation | novel | c.301N>A | p.Ala101Thr | p.A101T | Q96DA6 | protein_coding | tolerated(0.53) | benign(0.072) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC19 | SNV | Missense_Mutation | rs199774384 | c.251N>A | p.Arg84Gln | p.R84Q | Q96DA6 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| DNAJC19 | deletion | Frame_Shift_Del | c.348delN | p.Lys116AsnfsTer6 | p.K116Nfs*6 | Q96DA6 | protein_coding | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| DNAJC19 | SNV | Missense_Mutation | novel | c.198A>G | p.Ile66Met | p.I66M | Q96DA6 | protein_coding | deleterious(0) | possibly_damaging(0.715) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| DNAJC19 | SNV | Missense_Mutation | rs750384728 | c.58C>T | p.Arg20Cys | p.R20C | Q96DA6 | protein_coding | deleterious(0.01) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC19 | SNV | Missense_Mutation | rs199774384 | c.251G>A | p.Arg84Gln | p.R84Q | Q96DA6 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |